



07-18-05

IPW

Express Mail No. EV 452 775 784 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Koenig et al. Confirmation No.: 1191
Serial No.: 10/643,857 Art Unit: 1641
Filed: August 14, 2003 Examiner: To be assigned
For: FCyRIIB SPECIFIC ANTIBODIES AND Attorney Docket No.: 11183-010-999
METHODS OF USE THEREOF

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §1.97 & §1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby invite the Examiner's attention to the references A17, B06-B09 and C71 listed on the attached form PTO 1449 entitled "List of References Cited by Applicant." A copy of references B06-B09 and C71 is provided herewith. Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), copies of the cited U.S. Patents and U.S. Patent Application Publications are not submitted herewith. Also provided herewith is a PCT International Search Report from the counterpart International Application No. PCT/US03/26071.

Identification of the listed references is not meant to be construed as an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the references be made of record in the file history of the application.

Submission of this Supplemental Information Disclosure Statement is before the mailing date of the first Office Action on the merits; therefore, pursuant to 37 C.F.R. § 1.97(b), no fee is believed to be due for the filing of this Supplemental Information Disclosure Statement. Please charge any required fee, including any deficiencies in the amount estimated to be due, to Jones Day Deposit Account No. 50-3013. A duplicate of this sheet is enclosed for accounting purposes.

Respectfully submitted,

Date: July 15, 2005

40,922

Margaret B. Brivanlou
JONES DAY
222 East 41st Street
New York, NY 10017-6702
212-326-3939

(Reg. No.)

Enclosures



LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY DOCKET NO.
11183-010-999

APPLICATION NO
10/643,857

APPLICANT
Koenig et al.

FILING DATE
August 14, 2005

GROUP
1641

U.S. PATENT DOCUMENTS

MATTER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A17	5,837,243	11/17/1997	Deo et al.			

FOREIGN PATENT DOCUMENTS

MATTER		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B06	WO 99/58572 A1	11/18/1999	PCT				
	B07	WO 01/79299 A1	10/25/2001	PCT				
	B08	WO 03/066095 A2	08/14/2003	PCT				
	B09	EP 1 006 183 A1	06/07/2000	EP				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C71	Ding et al., Inhibition of the function of the FcγRIIB by a monoclonal antibody to thymic shared antigen-1, a Ly-6 family antigen. Immunology. 2001 Sep;104(1):28-36

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.